| [1] |
Mori T, Sugiyama M, Atomi Y. Gallstone disease: management of intrahepatic stones[J]. Best Pract Res Clin Gastroenterol, 2006, 20(6): 1117-1137.
|
| [2] |
Chen MF, Jan YY, Hwang TL, et al. Impact of concomitant hepatolithiasis on patients with peripheral cholangiocarcinoma[J]. Dig Dis Sci, 2000, 45(2): 312-316.
|
| [3] |
Hatzaras I, Schmidt C, Muscarella P, et al. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies[J]. HPB, 2010, 12(2): 134-138．
|
| [4] |
Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China[J]. World J Gastroenterol, 2008, 14(4): 632-635.
|
| [5] |
Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management[J]. Cancer Lett, 2015, DOI: 10.1016/j.canlet.2015.09.008[Epub ahead of print]. |
| [6] |
Liu ZY, Zhou YM, Shi LH, et al. Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study[J]. Hepatobiliary Pancreat Dis Int, 2011,10(6): 626-631.
|
| [7] |
Jo JH, Chung MJ, Park JY, et al. High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study[J]. Surg Endosc, 2013, 27(11): 4210-4216.
|
| [8] |
胡刚，湛汇，胡如进．肝内胆管结石合并肝内胆管癌发病危险因素及预测指标分析[J]．胃肠病学和肝病学杂志，2015, 24(6): 742-744.
|
| [9] |
Kim YT, Byun JS, Kim J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis[J]. Hepatogastroenterology, 2003, 50(49):8-12.
|
| [10] |
Suzuki Y, Mori T, Abe N, et al. Predictive factors for cholangiocarcinoma associated with hepatolithiasis determined on the basis of Japanese multicenter study[J]. Hepatol Res, 2012, 42(2):166-170.
|
| [11] |
Kuroki T, Tajima Y, Kanematsu T. Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms[J]. J Hepatobiliary Pancreat Surg, 2005, 12(6): 463-466.
|
| [12] |
Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma[J]. Semin Liver Dis, 2006, 26(1): 42-51.
|
| [13] |
Ishikawa A, Sasaki M, Sato Y, et al. Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis[J]. Hum Pathol, 2004, 35(12): 1505-1514.
|
| [14] |
Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt[J]. J Biol Chem, 2015, 290(29): 17806.
|
| [15] |
Lee KT, Liu TS. Expression of transforming growth factor betas and their signaling receptors in stone-containing intrahepatic bile ducts and cholangiocarcinoma[J]. World J Surg, 2003, 27(10): 1143-1148.
|
| [16] |
Zhou Q, Gong Y, Huang F, et al. Expression levels and significance of nuclear factor-κB and epidermal growth factor receptor in hepatolithiasis associated with intrahepatic cholangiocarcinoma[J]. Dig Surg, 2013, 30(4/6): 309-316.
|
| [17] |
晏建军，周飞国，曹杰，等．肝胆管结石合并肝内胆管癌的诊断与治疗（附18例报告）[J]．第二军医大学学报，2008, 29(10):1258-1260.
|
| [18] |
窦科峰，安家泽．复杂胆道结石与胆管癌[J]．中国实用外科杂志，2009, 29(7): 556-557.
|
| [19] |
黄志强．肝内胆管结石治疗演变和发展[J]．中国实用外科杂志，2015, 35(5): 468-470.
|
| [20] |
Uenishi T, Hamba H, Takemura S, et al. Outcomes of hepatic resection for hepatolithiasis[J]. Am J Surg, 2009, 198(2): 199-202.
|
| [21] |
Tabrizian P, Jibara G, Shrager B, et al. Hepatic resection for primary hepatolithiasis: a single-center Western experience[J]. J Am Coll Surg, 2012, 215(5): 622-626.
|
| [22] |
Chen DW, Tung-Ping Poon R, Liu CL, et al. Immediate and long-term outcomes of hepatectomy for hepatolithiasis[J]. Surgery, 2004, 135(4): 386-393.
|
| [23] |
Cheung MT, Kwok PC. Liver resection for intrahepatic stones[J]. Arch Surg, 2005, 140(10): 993-997.
|
| [24] |
Uchiyama K, Kawai M, Ueno M, et al. Reducing residual and recurrent stones by hepatectomy for hepatolithiasis[J]. J Gastrointest Surg, 2007, 11(5): 626-630.
|